Achieving an operating margin of 25% at ステムセル研究所 in approximately three years
First written in FY2022-Q3. 1 of 3 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2019: 14 of 100 companies on the "Worse" side.
16 other companies' latest entry also says "Raised".
- FY2023RaisedAnnual report
「As medium-term targets for the fiscal year ending March 2028, the company aims for a cell-storage rate of approximately 3% of all births in Japan and an operating margin of 30%.」
Stem Cell Research Institute has raised its operating-margin target from 25% within roughly 3 years to 30% for the fiscal year ending March 2028. - FY2022RestatedAnnual report
「The company has already established a cell processing center capable of handling three times its current scale. By strengthening marketing activities and promoting regenerative medicine using cells such as cord blood, it aims to increase stored specimens, improve its gross profit margin, and raise its operating margin to the near-term target of 25% over approximately 3 years.」
The company has reaffirmed its plan to target a 25% operating margin within roughly 3 years through cell-processing capacity, marketing, and the wider adoption of regenerative medicine. - FY2022-Q3First statedAnnual report
「The company has already established a cell processing center capable of handling three times its current scale. By strengthening marketing activities and promoting regenerative medicine using cells such as cord blood, it aims to increase stored specimens, improve its gross profit margin, and raise its operating margin to the near-term target of 25% over approximately 3 years.」
For Stem Cell Research Institute, a 25% operating margin is targeted within roughly 3 years, with expanded cell-processing capacity, marketing, the wider adoption of regenerative medicine, and an increase in stored specimens identified as the means of achieving it.